FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Releases Sekisui Medical FDA-483

FDA releases the FDA-483 issued following a 2016 inspection at Japans Sekisui Medical API manufacturer.

Biologics

Amgen BLA for Migraine Therapy

Amgen files a BLA for erenumab, a human monoclonal antibody for preventing migraine.

Lawyer Urges Whistleblower Case Discovery Stay

Attorney Stephen Wood says courts should require a stay of discovery in whistleblower cases until they have determined whether a case should be dismis...

Human Drugs

Supreme Court Rejects Lawyers Risperdal Appeal

The Supreme Court declines to hear an appeal of a 3rd Circuit Appeals Court ruling that a law firm lacks standing to challenge FDAs regulation of Jans...

Human Drugs

Administration Considers Capping NIH Indirect Costs

The Trump administration reportedly wants to save money in next years NIH budget by capping payments for research grant indirect costs at 10%.

Human Drugs

FDA Asked to Stay Roxybond NDA Approval

Pharmaceutical Manufacturing Research Services asks FDA to stay its approval of an Inspirion NDA for Roxybond.

Human Drugs

Court Dismisses Eliquis Case

Attorney James Beck says a New York federal court dismissed a suit against Bristol-Myers Squibb for not adding bleeding risk warnings to its Eliquis l...

Human Drugs

Oncology Excellence Center Handling Reviews: Pazdur

FDA Oncology Center of Excellence director Richard Pazdur outlines the Centers accomplishments since its 1/2017 founding.

Biologics

Spark Rolling BLA for Retinal Disease

Spark Therapeutics completes a rolling BLA submission for voretigene neparvovec, an investigational, one-time gene therapy for treating patients with ...

Medical Devices

FDA Clears Myoscience Pain Device for Knee Osteoarthritis

FDA clears a Myoscience 510(k) for its iovera device for relieving pain and symptoms associated with osteoarthritis of the knee for up to 90 days.